The Cold Ischemia Robot-assisted Partial Nephrectomy

NCT07326280 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Not applicable

Started

2024-01-01

Last updated

2026-01-08

Condition(s) studied

Renal Cell CarcinomaRenal Function Abnormal

Investigational drug(s) / intervention(s)

Cold ischemia robot-assisted partial nephrectomyWarm ischemia robot-assisted partial nephrectomy

Cold ischemia robot-assisted partial nephrectomy: During the surgical procedure, employing ice to achieve local hypothermia in the kidneys.

Warm ischemia robot-assisted partial nephrectomy: Not applying local hypothermia to the kidneys during the surgical procedure

Study summary

To establish evidence that cold ischemia, achieved through the use of ice slush, can improve the recovery from ischemia on the operated kidney in patients undergoing robot-assisted partial nephrectomy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: \- 18 to 80 years old; 2. Intending to perform robot-assisted partial nephrectomy Exclusion Criteria: * Anesthesiologist assessment: Patient unsuitable for general anesthesia; * Having severe cardiovascular and cerebrovascular diseases; * horseshoe kidney; * pregnant women

Primary outcome measure(s)

Recovery from ischemia — 1-12 months after surgery
(%GFR saved)/(%parenchymal mass preserved)

Trial sites (1)

Facility	City	Region	Status
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center；	Guangzhou	Guangdong	Recruiting

More Sun Yat-sen University trials in China

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Starting soon

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC Recruiting

Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases Recruiting

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study Recruiting

Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study) Recruiting

Other trials for the same condition

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy Starting soon

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Recruiting

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors Active, not recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07326280 on ClinicalTrials.gov ↗ ← All trials in China